

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A2

(51) International Patent Classification⁷: C12N 15/00 (74) Agent: BAYLISS, Geoffrey, Cyril; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(21) International Application Number: PCT/EP00/13149

(22) International Filing Date:
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9930691.2 24 December 1999 (24.12.1999) GB

(71) Applicant (*for all designated States except US*): DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwij-jaerde (BE).

(81) Designated States (*national*): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CI, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): PLAETINCK, Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). MORTIER, Katherine [BE/BE]; Paddenhoek 20, B-9830 St.-Martens-Latem (BE). LISSENS, Ann [BE/BE]; Tiensesteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).

Published:

— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2

WO 01/48183

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

- 1 -

IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA

INHIBITION

The present invention is concerned with ways of
5 improving the efficiency of double stranded RNA
inhibition as a method of inhibiting gene expression
in nematode worms such as *C. elegans*. In particular,
the invention relates to the finding that the
susceptibility of nematode worms such as *C. elegans* to
10 double stranded RNA inhibition is affected by changes
in the genetic background of the worms.

It has recently been described in Nature Vol 391,
pp.806-811, February 98, that introducing double
stranded RNA into a cell results in potent and
15 specific interference with expression of endogenous
genes in the cell, which interference is substantially
more effective than providing either RNA strand
individually as proposed in antisense technology. This
specific reduction of the activity
20 of the gene was also found to occur in the nematode
worm *Caenorhabditis elegans* (*C. elegans*) when the RNA
was introduced into the genome or body cavity of the
worm.

The present inventors have utilized the double
25 stranded RNA inhibition technique and applied it
further to devise novel and inventive methods of (i)
assigning functions to genes or DNA fragments which
have been sequenced in various projects, such as, for
example, the human genome project and which have yet
30 to be accorded a particular function, and (ii)
identifying DNA responsible for conferring a
particular phenotype. Such methods are described in
the applicant's co-pending application number WO
00/01846. Processes for introducing RNA into a living
35 cell, either *in vivo* or *ex vivo*, in order to inhibit
expression of a target gene in that cell are

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*.

- 5 One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence,
- 10 corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on

15 the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provided improved methods of double-stranded RNA inhibition.

Therefore, according to a first aspect of the

20 present invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence

25 substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild

30 type.

Caenorhabditis elegans is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes, preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type 5 generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type genetic background which confers greater sensitivity 10 to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying examples, introduction of double-stranded RNA (abbreviated herein to dsRNA) into a non wild-type 15 strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the phenotypic level as a more pronounced phenotype.

The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing susceptibility of the nematode to RNAi may, for example, affect the stability of dsRNA or the kinetics 25 of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding proteins involved in RNA 30 synthesis, RNA degradation or the regulation of these processes.

In one preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more 35 nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

nucleases, such as RNases. A particularly preferred example is the *nuc-1* strain. This mutant *C. elegans* strain is known *per se* in the art.

In a second preferred embodiment, the nematode is 5 a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode 10 may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

The term "increased gut uptake" as used herein is taken to mean increased uptake of foreign particles 15 from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

C. elegans feeds by taking in liquid containing its food (e.g. bacteria). It then spits out the 20 liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called pharyngeal pumping. Once the food particles have been 25 internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which effect the uptake of compounds from the gut lumen to the surrounding tissues. These include the action of multi-drug resistance proteins, multi-drug resistance 30 related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport of molecules through the gut wall.

C. elegans mutants which exhibit increased uptake 35 of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the C.

elegans Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "C. elegans: Modern 5 biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms 10 exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms 15 may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

20 Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker 25 molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and 30 maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not 35 fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530
5 nm.

Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the
10 invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, Gent, Belgium under accession number LMBP 5334CB. The
15 phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which
20 results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun
25 mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either *nuc-1* or gun single mutants.

For the avoidance of doubt, where particular
30 characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans*, wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, *Caenorhabditis elegans: Modern biological analysis of an organism*, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode *Caenorhabditis elegans*, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans II*, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.

Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food 5 organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that variations in the food organism can result in enhanced 10 *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said 15 nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a 20 modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can be any modification which results in increased 25 expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which have a direct effect on the rate of transcription. In 30 a preferred embodiment, the food organism is an RNase III minus *E. coli* strain, or any other RNase negative strain.

According to a still further aspect of the invention there is provided a method of inhibiting 35 expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

1] sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

5 In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing
10 double-stranded RNA structures following ingestion into a nematode.

In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that
15 they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

Several different arrangements of promoters may
20 be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical.

Transcription from the opposable promoters produces
25 two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate
30 sequence, corresponding to a region of a target gene. pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans unc-22* gene. In an alternative arrangement, DNA fragments corresponding to a region of the target gene may be placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the
35 sense/antisense fragments are co-transcribed to

- 10 -

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of 5 which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate 10 polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics. 15 Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire 20 in Methods in Cell Biology, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in 25 a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance 30 with the method of the invention can be achieved using a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking 35 T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode,
5 resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate
10 complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for
15 inhibition.

It is preferred to use dsRNA comprising a nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor variations such as insertions, deletions and single
20 base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as used herein is to be interpreted accordingly. Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence
25 identity. Sequence identity may be conveniently calculated based on an optimal alignment, for example using the BLAST program accessible at WWW.ncbi.nlm.nih.gov.

The invention will be further understood with reference to the following non-limiting Examples,
30 together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

5 Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans unc-22* gene cloned in pGN1).

10 15 Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

20 25 Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc.).

Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

25 Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

30 35 Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

- 13 -

plasmid pGX22.

Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 5 liquid culture were fed with *E. coli* containing the plasmid pGX52.

Figure 11 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 10 liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

Figure 12 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 15 liquid culture were fed with *E. coli* containing the plasmid pGX104

Example 1

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

5 **Introduction**

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA. The possibility of DNA delivery and dsRNA delivery has previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

15 For this experiment the following *E. coli* strains were used:

1. MC1061: F-*araD139* Δ(*ara-leu*)*7696* *galE15* *galK16* Δ(*lac*)*X74* *rpsL* (*Str*^r) *hsdR2* (*r_k*⁻ *m_k*⁺) *mcrA* *mcrB1*
 - regular host for various plasmids,
 - Wertman et al., (1986) Gene 49:253-262,
 - Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.
- 25 2. B21(DE3): F- *ompT(lon)* *hsdS_B* (*r_B*⁻,*m_B*⁻; an *E. coli* B strain) with DE3, a λ prophage carrying the T7 RNA polymerase gene.
 - regular host for IPTG inducible T7 polymerase expression,
 - Studier et al. (1990) Meth. Enzymol. 185:60-89
- 30 3. HT115 (DE3): F- *mcrA* *mcrB* IN(*rrnD-rrnE*) 1 λ-*rnc14::tr10* (DE3 lysogen: *lacUV5* promoter-T7polymerase)
 - host for IPTG inducible T7 polymerase

- 15 -

- expression,
- RNaseIII-,
- Fire A, Carnegie Institution, Baltimore, MD,
Pers. Comm.

5

For this experiment the following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
- 10 2. *C. elegans nuc-1(e1393)*: *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death; ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described:
e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
- Stanfield et al. (1998) East Coast Worm meeting abstract 171,
- Anonymous, Worm Breeder's Gazette 1(1):17b
Hevelone et al. (1988) Biochem. Genet. 26:447-461
- Ellis et al., Worm breeder's Gazette 7(2):44
- Babu, Worm Breeder's gazette 1(2):10
- Driscoll, (1996) Brain Pathol. 6:411-425
- Ellis et al., (1991) Genetics 129:79-94

15

20

25

For this experiment the following plasmids were used:

- 30 pGN1: A vector encoding for ampicillin resistance, harbouring a multiple cloning site between two convergent T7 promoters.

- pGN8: pGN1 containing a genomic fragment of unc-22.
35 Decreased unc-22 expression via RNAi results in a "twitching" phenotype in *C. elegans*.

Experimental conditions

12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml 5 cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M CaCl₂, 9.5 ml 0.1 ml MgSO₄, 25 ml 1M KH₂PO₄/K₂HPO₄ buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH₃COONH₄ 7.5 M).

10

The dried plates were spotted with approximately 50 µl of an overnight culture of bacteria. When IPTG induction was required, 50 µl of a 10 mM stock solution of IPTG was dropped on top of the bacteria lawn, and incubated at 37°C for approximately 4 hours. Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of 15 the seeded nematodes were tested for the twitching phenotype.

20

Results

Table 1: Percentage of the offspring that show the twitching phenotype

	MC1061	N2	<i>nuc-1</i>
5	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	0%	0%
	pGN8 + IPTG	0%	0%
10	BL21 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	20% (+)	>90% (++)
	pGN8 + IPTG	20% (+)	>90% (++±)
15	HT115 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	50% (+±)	>90% (++)
	pGN8 + IPTG	80% (++)	>90% (+++)
20			

%: percentage twitchers

+: weak twitching

++: twitching

+++: strong twitching

25

Conclusions

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment.

30 Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the unc-22 fragment cloned in pGN8 is not

expressed as dsRNA.

- The experiment with *E. coli* strain BL21(DE3) and nematode strain N2 shows expected results. BL21(DE3) harbouring plasmid pGN1 does not result in any twitching as the pGN1 vector is an empty vector. BL21 (DE3) harbouring PGN8 results in the expression of unc-22 dsRNA. When this dsRNA is fed to the N2 nematode (indirectly by feeding with the bacteria that produce the dsRNA), this results in a twitching phenotype, indicating that the dsRNA is able to pass the gut barrier and is able to perform its interfering activity.
- Surprisingly the RNAi effect of the unc-22 dsRNA was even more pronounced in *C. elegans* strain *nuc-1* than in the wild type N2 strain. Although one may expect that the *nuc-1* mutation results in the non-degradation or at least in a slower degradation of DNA, as the NUC-1 protein is known to be involved in DNase activity, we clearly observe an enhancement of the RNAi induced phenotype in *C. elegans* with a *nuc-1* background. The *nuc-1* mutation has not been cloned yet, but it has been described that the gene is involved in nuclease activity, and more particularly DNase activity. If the NUC-1 protein is a nuclease, it may also have activity on nuclease activity on dsRNA, which would explain the enhanced RNAi phenotype. The *nuc-1* gene product may be a nuclease, or a regulator of nuclease activity. As the mode of action of RNAi is still not understood, it is also possible that the NUC-1 protein is interfering in the mode of action of RNAi. This would explain why a *nuc-1* mutant is more sensitive to RNAi.

35

The experiment with the *E.coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain. The RNA interference observed with the unc-22 dsRNA is even higher. In comparison with strain BL21(DE3) this could be expected, as HT115(DE3) is a RNase III minus 5 strain, and hence is expected to produce larger amounts of dsRNA, resulting in more prominent RNAi. This indicates further that the RNAi observed in this experiment is the result of the dsRNA produced by the bacteria fed to the *C. elegans*. Feeding *C. elegans* 10 *nuc-1* with HT115(DE3) harbouring pGN8 also results in higher RNA interference phenotype than feeding the same bacteria to *C. elegans* wild-type strain N2. Once again this indicates that improved RNAi can be realised using a nuclease negative *C. elegans* and more 15 particularly with a with the *C. elegans nuc-1* (e1392) strain.

Summary

RNA interference can be achieved in *C. elegans* by 20 feeding the worms with bacteria that produce dsRNA. The efficiency of this RNA interference is dependent both on the *E. coli* strain and on the genetic background of the *C. elegans* strain. The higher the level of dsRNA production in the *E. coli*, the more 25 RNAi is observed. This can be realised by using efficient RNA expression systems such as T7 RNA polymerase and RNAase negative strains, such as RNaseIII minus stains. In this example the level of dsRNA production varied: HT115(DE3)>BL21(DE3)>MC1061.

30 RNA interference is high in *C. elegans* strains that are nuclease negative, or that are influenced in their nuclease activity. This can be realised by using a mutant strain such as *C. elegans nuc-1*.

35 In this example the sensitivity to RNAi varied:
C. elegans nuc-1 >> *C. elegans N2*

Example 2

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake. (designated herein 'gun' mutants). Strains bg77, bg78, bg83, bg84, bg85, bg86, bg87, bg88 and bg89 are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

10

Experimental conditions:

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100 μ g/ml) and 5 ml of 100mM stock IPTG) per well
- the dried plates were spotted with 25 μ l of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- individual nematodes at the L4 growth stage were then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- the adult F1 offspring of the seeded nematodes were tested for the twitching phenotype

Results:

Table 2:

20°C/6d	pGN1 RT115DE3	pGN8 BL2DE3	pGN8 HT115DE3	
N2	0	1	1	
bg77	0	1-2	1	
bg78	0	1-2	1	
bg79	0	1	1-2	
bg80	0	1	1	
bg81	0	1	1	
bg82	0	1	1	
bg83	0	1	1	
bg84	0	1-2	1	
bg85	0	1	1	
bg86	0	1	1	
bg87	0	1	1	
bg88	0	1	1	
bg89	0	1	1	

figure legend:

- 0 = no twitching
- 1 = no to weak phenotype
- 2 = clear phenotype
- 3 = strong phenotype

25 **Conclusions**

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1* *C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains bg77, bg84, bg85, bg86 show improved sensitivity to RNAi compared to Wild-type.

- 22 -

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

5 Double mutants were constructed to test the prediction that gun/nuc mutants would even show more enhanced RNAi sensitivity. As an example, the crossing strategy with gun strain bg85 is shown, similar crosses can be conducted with other gun strains, such
10 as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

15 F1 cross: nuc-1 x gun(bg85)/+ males

F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)
nuc-1 x +/++; nuc-1/0 males (50%)

20 F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)
+/++; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th
plate high staining with BCECF)

25 F5 retest: gun(bg85); nuc-1 (100% progeny of F4
singled high staining with BCECF)

To select for the gun phenotype, the fluorescence precursor BCECF-AM is used (obtainable from Molecular
30 probes). The precursor BCECF-AM is cleaved by esterases present in the gut of the worm to generate the dye BCECF which is fluorescent at pH values above 6. This allows selection for worms that have a gun phenotype. BCECF-AM is taken up through the pharynx
35 into the gut lumen and is not fluorescent until it has been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

5 **Example 3**

Improved RNAi feeding in liquid culture using *nuc-1*(e1393) *C. elegans*.

Introduction

10 N2 and *nuc-1* *C.elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using 15 the *nuc-1* strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E.coli* strains were used:

- 20
1. HT115 (DE3): F- *mcrA mcrB IN(rrnD-rrnE)* 1 λ-
rnc14::tr10 (DE3 lysogen: lacUV5 promoter -T7 polymerase)
 - host for IPTG inducible T7 polymerase expression
 - RNaseIII-
 - Fire A, Carnegie Institution, Baltimore, MD,
Pers. Comm.
- 25

For this experiment, following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;

ingested (bacterial) DNA in the intestinal lumen
is not degraded. Several alleles are described:
e1392 (strong allele: has been used for the
experiments described below); n887 (resembles
5 e1392) and n334 (weaker allele)

- Stanfield et al. (1998) East Coast Worm meeting
abstract 171
- Anonymous, Worm Breeder's Gazette 1(1):17b
- Hevelone et al. (1988) Biochem. Genet. 26:447-461
- 10 - Ellis et al., Worm breeder's Gazette 7(2):44
- Babu, Worm Breeder's gazette 1(2):10
- Driscoll, (1996) Brain Pathol. 6:411-425
- Ellis et al., (1991) Genetics 129:79-94

15

For this experiment, the following plasmids that all
give lethal phenotypes in *C. elegans* via RNAi were
used:

20 pGX22: a vector encoding ampicillin resistance,
containing a genomic fragment of cosmid C04H5.6
corresponding to a member of the RNA helicase family.

25 pGX52: a vector encoding ampicillin resistance,
containing a genomic fragment of cosmid K11D9.2b
corresponding to sarco/endoplasmic Ca²⁺ ATPase also
known as SERCA.

30 pGZ18: a vector encoding ampicillin resistance,
containing a genomic fragment of cosmid T25G3.2
corresponding to a chitin like synthase gene.

35 pGX104: a vector encoding ampicillin resistance,
containing a genomic fragment of cosmid Y57G11C.15
corresponding to sec-61, a transport protein.

Experimental conditions

- 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended
5 in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with
10 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 15 3 nematodes at the L1 growth stage of N2 and nuc-1 strain were then placed in single wells, 3 L1's per well. Per experimental set up, 16 wells were used (n=16).
- 20 the plates were incubated at 25°C for 5 days to allow offspring to be formed.
- the plates were visually checked and the following phenotypes could be scored per individual well:

25 no effect: L1's developed to adults and gave normal offspring.

no F1 offspring: L1's developed to adults and gave no offspring.

30 acute lethal: original L1 did not mature and died.

Results

- 35 The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

- 26 -

a percentage of the total (n=16) on the y-axis for both N2 and nuc-1 strains.

Conclusions

5 The following genes were tested in this liquid RNAi assay:

- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
- 10 - SERCA: a sarco/endoplasmic Ca^{2+} ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- T25G3.2: a chitin like synthase gene. RNAi of this gene causes dead eggs.
- 15 - sec-61: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 20 - RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the nuc-1 *C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This 25 is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and Sec-61 the difference between the N2 wild-type strain and the nuc-1 stain is less pronounced.

30

- 27 -

Example 4

Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi

A set of primers for each gene was designed on the basis of sequence data available in the publicly

5 accessible *C. elegans* sequence database (Acedb).

The cosmid names relate to:

- 10 1. C04H5.6=member of RNA helicase
 2. K11D9.2b=SERCA
 3. Y57G11C.15=transport protein sec-61
 4. T25G3.2=chitin synthase like

The following primer sequences were designed:

- 15 1. C04H5.6F 5'-TGCTCAGAGAGTTCTAACGAACC-3'
 C04H5.6R 5'-CAATGTTAGTTGCTAGGACCACTG-3'

 2. K11D9.2bF 5'-CAGCCGATCTCCGTCTTGTG-3'
 K11D9.2bR 5'-CCGAGGGCAAGACAACGAAG-3'

 3. Y57G11C.15F 5'-ACCGTGGTACTCTTATGGAGCTCG-3'
 Y57G11C.15R 5'-TGCAGTGGATTGGGTCTTCG-3'

25 4. T25G3.2F
 5'-GGGGACAAGTTGTACAAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'

 T25G3.2R
 5'-GGGGACCACCTTGTACAAGAAAGCTGGTTGGAGAAGCATTCCGAGAGTTG-3'

30

PCR was performed on genomic DNA of N2 strain *C. elegans* to give PCR products of the following sizes:

- 35 1326bp for C04H5.6
 1213bp for K11D9.2b

1024bp for Y57G11C.15

1115bp for T25G3.2

- 5 The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15
were linked to *Bst*XI adaptors (Invitrogen) and then
cloned into the pGN29 vector cut with *Bst*XI. pGN29
contains two T7 promoters and two T7 terminators
flanking a cloning site which is adapted for
facilitated cloning of PCR fragments, comprising a
10 stuffer DNA flanked by two *Bst*XI sites (see schematic
Figure 3). The resulting plasmids were designated
pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104
(Y57G11C.15).
- 15 The PCR fragment of T25G3.2 was cloned into pGN39 via
recombination sites based on the GATEWAY™ cloning
system (Life Technologies, Inc). pGN39 contains two
T7 promoters and two T7 terminators flanking a cloning
site which facilitates "High Throughput" cloning based
20 on homologous recombination rather than restriction
enzyme digestion and ligation. As shown schematically
in Figure 4, the cloning site comprises *att*R1 and
*att*R2 recombination sites from bacteriophage lambda
flanking a gene which is lethal to *E. coli*, in this
25 case the *ccdB* gene. This cloning site is derived from
the Gateway™ cloning system commercially available
from Life Technologies, Inc. The Gateway™ cloning
system has been extensively described by Hartley et
al. in WO 96/40724 (PCT/US96/10082).

Example 5

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

5

The screen was performed in *unc-31*(e928) mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

10 15

Mutagenesis

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

20 Day 2: P0 was divided over several large agar plates

Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's layed were checked every hour and de F1's were removed when 10-20 eggs per F1 were counted

25 Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

30

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x) 9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

35

Table 3: Isolation of mutations for increased staining with BCECF-AM

	Total P0 (counted)	Total F1 (estimated)	Total F2 (calculated)	screened chromosomes (estimated)	number of strains isolated (counted)
5	2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

- 10 1. backcrossing *unc-31; gun* --> *unc-31; gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains segregating 1/4 unc
- 15 15 stain unc strains with BCECF-AM
 - from positive strains pick unc homozygous
 - retest 100 % unc strains with BCECF-AM
 - kept 1 strain (backcrossed)
- 20 20 2. *unc-31* background was crossed out-->+; *gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains which did not segregate unc F3s
- 25 25 anymore
 - stain non unc strains with BCECF-AM
 - 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)
- 30 30 3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
 - *gun* x WT males
 - WT hermaphrodites x F1 males (*gun/+*)
 - singled 10 WT hermaphrodites F2s (1/2 heterozygous)
- 35 35 - singled 50 WT hermaphrodites F3s (1/8 homozygous)

- 31 -

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1(X)*
- 5 mutant--> *gun; nuc-1*
- *gun* x WT males
 - *nuc-1* x *gun/+* males
 - *nuc-1* x *gun/+; nuc-1/0* or *+/+*; *nuc-1/0* males
 - singled 10 WT hermaphrodite progeny (*nuc-1* homozygous, $\frac{1}{2}$ heterozygous *gun*)
 - singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)
 - stain strains with BCECF-AM
 - retested positives with BCECF-AM and finally 1 was selected and kept

Table 6: Strains derived from *gun* mutations

20	<i>gun</i>	<i>unc-31; gun</i>		<i>unc-31; gun</i>		<i>+/; gun</i>			<i>gun; nuc-1</i>
		original isolate		backcrossed (1x)		outcrossed (1x)		3x b.c.	from 3x b.c.
allele number	Isolation number	strain number	Isolation number	strain number	Isolation number	strain number	strain number	strain number	strain number
bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674	UG 777	
bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675		-
bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676		-
bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677	UG 774	
bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717		UG 775	
bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678	UG 776	
bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679		-
bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680		-
bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671		-

SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

5 SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

SEQ ID NO: 4 complete sequence of pGN39

10 SEQ ID NO: 5 complete sequence of pGX22

SEQ ID NO: 6 complete sequence of pGX52

15 SEQ ID NO: 7 complete sequence of pGX104

SEQ ID NO: 8 complete sequence of pGZ8

SEQ ID NO: 9 primer C04H5.6F

20 SEQ ID NO: 10 primer C04H5.6R

SEQ ID NO: 11 primer K11D9.2bF

25 SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

SEQ ID NO: 14 primer Y57G11C.15R

30 SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.
2. A method as claimed in claim 1 wherein the nematode is a microscopic nematode.
3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.
4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.
5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic background.
6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild type.
7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain *nuc-1*.
8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

5

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which 10 results in increased gut uptake compared to wild type.

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

15

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

20

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

25

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

30

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

35

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

5

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

10

18. A method as claimed in claim 26 wherein the two promoters are identical.

15

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

25

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

30

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

35

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28 to 31 wherein the nematode has a mutant genetic
5 background.

33. A method as claimed in claim 32 wherein the nematode is mutant *C. elegans* strain bg85.

10 34. A method as claimed in any one of claims 28 to 33 wherein the DNA capable of producing a double-stranded RNA structure is a vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of initiating
15 transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

20 35. A method as claimed in claim 34 wherein the vector comprises two promoters flanking the DNA sequence.

25 36. A method as claimed in claim 35 wherein the two promoters are identical.

30 37. A method as claimed in claim 34 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

35 38. A method as claimed in any one of claims 34 to 37 wherein the nematode is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

39. A method as claimed in any one of claims 34

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

5 24. A method as claimed in claim 23 wherein the food organism is a bacterium.

10

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

15 26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNase III minus strain or any other RNase negative strain.

20 27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

25 28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

30

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

35 30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

- 38 -

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

FIG. 1




FIG. 2.




FIG. 3.




FIG. 4.





FIG. 5.

FIG. 6.




FIG. 7.




FIG. 8.




FIG. 9.




FIG. 10.




FIG. 11.





FIG. 12.



1
SEQUENCE LISTING

<110> DEVGEN NV

<120> IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

<130> SCB/53711/001

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 3216

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN1

<400> 1

gagtgcacca tatgcggtgt gaaataccgc acagatcggt aaggaaaaa taccgcata 60
ggcggaaattt gtaaacgttaa tattttgtta aaattcgctgt taaatatttgc tttaatcagc 120
tcattttta accaataggc cggaaatcgcc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggt tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aaggggcgaaa aaccgtctat cagggcgatg gcccaactacg tgaaccatca 300
cccaaataa gtttttttgcg gtcgagggtgc cgtaaagctc taaatcgaa ccctaaagg 360
agcccccgat tttagagcttg acggggaaag cggcgaaacg tggcgagaaa ggaagggaag 420
aaagcgaaag gagcgggcgc tagggcgtg gcaagtgttag cggtcacgtc ggcgttaacc 480
accacaccccg cccgcgttaa tgcgcgcgt cagggcgatg ccattcgcca ttcaaggctgc 540
gcaactgttg ggaagggcgaa tcgggtcgccc ctcttcgtt attacgcacg ctggcgaaag 600
ggggatgtgc tgcaggcgaa ttaagttggg taacgccagg gttttcccgat tcacgacgtt 660
gtaaaacgac gcccagtgaa ttgtataacg actcaactata gggcgaattc gagtcggta 720
cccggggatc ctctagatgc gaaagcttct cgccctatag tgagtcgtat tacagcttga 780
gtatttata gtgtcaccta aatagcttgg cgtaatcatgt gtcatacgct tttcctgtgt 840
gaaattgtta tcggctcaca attccacaca acatacgacg cggaaagcata aagtgtaaag 900
cctggggatc ctaatgagtg agctaactca cattaattgc gttgcgtca ctggccgtt 960
tccagtcggg aaacatgtcg tgccagctgc attaatgaat cggccaaacgc gggggagag 1020
gcccgttgcg tattgggcgc tcttccgctt cctcgctcac tgactcgctg cgctcggtcg 1080
ttcggctgcg gcgagcggtc tcagctact caaaaggcggt aatacggta tccacagaat 1140
caggggatata cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgt 1200
aaaaggccgc gttgtggcg ttttcgata ggctccgcgc ccctgacgag catcacaaaa 1260
atcgacgttc aagttagagg tggcgaaacc cgacaggact ataaagatac cagcggttc 1320
cccctggaaat cttccctcggt cgctctctgt ttccgaccct gccgcttacc ggataacctgt 1380
ccgccttctt cccctcggtt agcgtggcgc tttctcatag ctcacgctgt aggtatetca 1440
gttcgggtgtt ggtcggttcg tccaaagctgg gctgtgtgc cgaacccccc gttcagcccg 1500
accgctgcgc ctatcccggt aactatcgtc tttagtccaa cccggtaaga cacgacttat 1560
cgccactggc agcagccact ggtAACAGGA tttagcagacg gaggtatgtt ggcgggtcta 1620
cagagtctt gaagtgggtt cctaactacg gctacactag aaggacagta tttggtatct 1680
gcgctctgtc gaagccaggat accttcggaa aaagagttgg tagctctgtt tccggcaaac 1740
aaaccaccgc tggtagcggt ggtttttttt ttgcaagca gcagattacg cgccagaaaa 1800
aaggatctca agaagatctt ttgatctttt ctacgggggtc tgacgctcag tggAACGAAA 1860
actcacgtta aggattttt gtcgtatggat tatcaaaaag gatcttcacc tagatccttt 1920
taaattaaaa atgaagttt aaatcaatct aaagtatata tgtagtaact tggcttgaca 1980

2

gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctattt	cgttcatcca	2040
tagttgcctg	actccccgtc	gtgttagataa	ctacgataacg	ggaggggctta	ccatctggcc	2100
ccagtgctgc	aatgataccg	cgagaccac	gctcacccggc	tccagattta	tcagcaataa	2160
accagccagc	cggaaagggcc	gagcgcagaa	gtggccctgc	aactttatcc	gcctccatcc	2220
agtctattaa	tttgtgccgg	gaagctagag	taagttagttc	gccagttaat	agtttgcgca	2280
acgttgttgg	cattgttaca	ggcatcgtgg	tgtcacgcgc	gtcggttgg	atggcttcat	2340
tcaagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgttg	tgcaaaaaag	2400
cggtagtctc	cttgcgtctt	ccgatcgttg	tcagaagtaa	gttggccgca	gtgttatcac	2460
tcatggttat	ggcagcactg	cataatttctc	ttactgtcat	gccatccgta	agatgtttt	2520
ctgtgactgg	tgagttactca	accaagtcat	tctgagaata	ccgcgcggc	cgaccgagtt	2580
gctcttgccc	ggcgtcaata	cgggataata	gtgtatgaca	tagcagaact	ttaaaagtgc	2640
tcatcatatgg	aaaacgttct	tcggggcgaa	aactctcaag	gatcttacgg	ctgttgagat	2700
ccagttcgat	gtaaaccact	cgtgcaccca	actgatcttc	agcatcttt	actttcacca	2760
gcgtttctgg	gtgagaaaaa	acaggaaggc	aaaatgcccgc	aaaaaaaggga	ataagggcga	2820
cacggaaatg	ttgaataactc	ataactctcc	tttttcaata	ttattgaagc	atttatcagg	2880
gttattgtct	catgagcgga	tacatatttgc	aatgtatTTA	aaaaaaataaa	caaatagggg	2940
ttccgcgcac	atttccccga	aaagtgcac	ctgacgtctt	agaaaaccatt	attatcatga	3000
cattaaccta	taaaaaatagg	cgtatcacga	ggccctttcg	tctcgcgcgt	ttcgggtatgt	3060
acggtgaaaa	cctctgacac	atgcagctcc	cggagacgggt	cacagttgt	ctgttaagcggt	3120
atgcggggag	cagacaagcc	cgtcaggcg	cgtcagcggg	tgttggcggg	tgtcgccgt	3180
ggcttaacta	tgccggcatca	gagcagatttgc	tactgt	.		3216

<210> 2

<211> 4620

<212> DNA


<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN8

<400> 2

gatccgaatc tccatgtctg ttaacagccct tgacacggaa ttatattca tgcccttgag 60
tcaaatcgctc aacgtggaaat ttggtatct tgctctctcc gcaagcagtc catctgccag 120
tggcagcatc ttgttttca atgacatagt gactgatttc agctctcca tcatcttctg 180
gttccttcca tgcaagatca catccatct tgacaatatt agtgacatcg agaggccac 240
gtgggcttga tggatgatca agaacagtaa ccttcaacttc agcagtgtca gttcattct 300
cgttctctgc cttgatgata taggttctg tatccgaacg caaagcttc ttcatcgatg 360
attttagtctt gccgtttca ttgttcaact tcatacgatc atcagattcg actgtgttc 420
cttcgaaagt ccaagtaatt gttggaggta gttcaccact gactggaatg ttcaatgaga 480
agtcttgc acgccttgacc ttgatttctt gaatcgagtt acgatcgatg actgtggaa 540
ctataattta attcaatgat tatttagtaat tgatttagac tcttaccatt tctagcctt 600
gcaacagctg atgctgaatc agatggatct cccaaatctg ccttgttctt ggcacggatt 660
ctgaattcgt actttgatcc ttcccttgaga ttccaacag tagcattcgt ttgtccagct 720
ggaacatgag caacgtcatt ccagaatggc gagaactcgt cttcatctc aacaacgtat 780
tcctcgattt gaggaccacc gtcgttgc ggtggcttcc attcaaggc aacatgatcc 840
ttatcccaat cagtaattt aggagcattt gtcttcctg gcttgtcaaa tggatcttgc 900
gcaagtgtgg ttccgaaggt ctccaaatggc tcggactctc cttcagcatt gacggcagcg 960
acacggaaact gaaaatcaaa atgttgcattt caattgagtt caagattaaa aaattctcac 1020
tttatattca tggccaggaa taagaccgtc aacaacagct gtatgtttat ctccagcgac 1080
ctttgcagct ggaacccatc ttccacttgc agtacgtac ttttgcattca catagttttc 1140
aatttggaaata cttccatcat catctggtc acgccaattt aaagtgcattt gatcaccatg 1200
aacatcgaa acatctaatg gaccatttgg agaagttggc ttgtctgaaa attttaaaata 1260
taaccaaattt aatttggaaat aactaatgtc caccataaac atttgcattca acatgttgc 1320
catcttctcc atttgcattt acagcttgc tagtggaaatg tccactgtct ccacgttcca 1380
tttgcattca accagctttt gattggattt ctgggttac aagcttctcg ccctatagt 1440
agtcgttata cagcttgatg attctatgt gtcacccaaa tagcttggcg taatcatgg 1500
catagctgtt tcctgtgtga aatttgcattt cgctcacaat tccacacaac atacgagccg 1560
gaagcataaa gtgtaaagcc tgggggtgcct aatgagtgag ctaactcaca ttaatttgcgt 1620



catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tggtagatc 3420
 cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatcttta ctttcaccag 3480
 cgtttctggg tgagcaaaaa caggaaggca aaatgccgc aaaaaggaa taagggcgac 3540
 acggaaatgt tgaatactca tactttctt tttcaatat tattgaagca ttatcaggg 3600
 ttattgtctc atgagcgat acatatttg atgtatTTAG aaaaataaac aaatagggt 3660
 tccgcgcaca ttcccggaa aagtgcacc tgacgtctaa gaaaccatta ttatcatgac 3720
 attaacctat aaaaataggc gtatcacag gcccTTTGTG ctcgcgcgt tcggtgatga 3780
 cggtaaaac ctctgacaca tgcagctccc ggagacggc acagctgtc tggtaagcgga 3840
 tgccgggagc agacaagccc gtcaggcgc gtcagcggt gttggcggt gtcgggctg 3900
 gcttaactat gcggcatcg agcagatgt actgagatg caccatatgc ggtgtgaaat 3960
 accgcacaga tgcgtaaagg gaaaataccg catcaggcga aattgtaaac gttaatattt 4020
 tggtaaaatt cgcgttaat aittgttaaa tcagcttattttttaaccaa taggcccggaa 4080
 tcggccaaat cccttataaa tcaaaaagaat agaccgagat agggttttagt gttgttccag 4140
 tttggaaaca gagtccacta ttaaagaacg tgacttccaa cgtcaaaaggc cggaaaaccg 4200
 tctatcaggc cgtatggccca ctacgtgaac catcacccaa atcaagggtt ttgcgggtcg 4260
 ggtgcgtaa agctctaaat cggAACCTTA aaggggagccc cggattttaga gctgacggg 4320
 gaaagccggc gaacgtggcg agaaaggaa ggaagaaaacg gaaaggagcg ggcgcgtagg 4380
 cgctggcaag ttagcggtc acgctgcgc taaccaccac acccgccgcg cttaatgcgc 4440
 cgctacaggg cgcgtccatt cgccattcag gctgcgcac tggggaaag ggcgcgtt 4500
 gcgggcctct tgcgtattac gccagctgc gaaagggggg tggctgtcaa ggcgatctaag 4560
 ttgggttaacg ccagggtttt cccagtcacg acgttggaaacgacgcgcgtt gttgttgc 4620
 atacgactca ctatagggcg aattcaaaaa acccctcaag acccggtttag agggcccaag 4680
 gggttatgtc agtgaattct gcagggtacc cggggatcct ctagagatcc ctcgacactcg 4740
 agatccatttgc tgctgg 4756

<210> 4

<211> 4643

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX52

<400> 4

gagtgaccca tatgcgggtg gaaataccgc acagatgcgt aaggagaaaa taccgcata 60
 ggcgaaattt gtaaacgttta tattttgtta aatttcgcgt taaatattt ttaatcagc 120
 tcattttta accaataggc cggaaatccgc aaaaatccctt ataaatcaaa agaatagacc 180.
 gagatagggt ttagtgggtg tccagttgg aacaagatc cactattaaa gaaatggac 240
 tccaaacgtca aaggggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
 cccaaatcaa gtttttgcg gtcgagggtgc cgtaaagctc taaatcgaa ccctaaagg 360
 agcccccgat ttagagctt acggggaaag cccgcgaacg tggcgagaaa ggaaggaaag 420
 aaagcgaaag gacggggcgc tagggcgctg gcaagtgtag cggtcacgtc ggcgttaacc 480
 accacaccgc cccgcgttta tgcgcgcata cagggcggtt ccattcgcca ttcaaggctgc 540
 gcaactgtt ggaaggggcgta tcggtgccgg cctcttcgtt attacgcccatttgcgaaag 600
 ggggatgtgc tgcaggcgta ttaagtggg taacgcggg gtttcccag tcacgacgtt 660
 gtaaaaacgc gcccagtgtaa ttgtataacg actcaactata gggcgaaattc aaaaaacc 720
 tcaagacccg ttagaggcc ccaagggtt atgcttagtga attctgcagg gtacccgggg 780
 atccctctaga gatccctcgatc cctcgagatc cattgtgtcg tgcagccgtc tccgttctgt 840
 gaagatctac tccaccacca tccgtatcgatc tcagtcattt ctcaccggag aatctgtgtc 900
 tggatcaag cacaccgact ctgtgcaga tccacgcgtt gtttaccagg acaagaagaa 960
 ttgtctgttc tcgggaacca atgtcgatc tggaaaggct cgtggatcg tcttcggaaac 1020
 cggattgacc actgaaatcg gaaagatccg taccgaaatg gctgagaccc agaatgagaa 1080
 gacaccactt caacagaagt tggacgaaattt cggagacggaa ctttccaagg ttatctctgt 1140
 tatttgcgtt gctgtttggg ctatcaacat tggacatttc aacgatccag ctcacgggtgg 1200
 atcatgggtt aaggggagccaa tctactactt caaaatcgcc gttgcttgc cgcgtcgtc 1260
 tattccagaa ggacttccag ctgtcatcactt caccgtgcctt gcccctggaa ctcgcccgtat 1320
 ggccaagaag aacgcttattt taagatccct tccatccgtc gaaactctt gatgcacatc 1380
 tggatctgc tctgacaaga ctgaaactt caccaccaac cagatgtctg tgtcaagat 1440

6

gttcatcgct ggacaagctt ctggagacaa catcaacttc accgagttcg ccatctccgg 1500
atcccacctac gagccagtgc gaaaggttc caccatggc cgtaaatca acccagctgc 1560
tggagaattc gaatcactca ccgagttgc catgatctgc gctatgtca atgattcatc 1620
tgttgattac aatgagacca agaagatcta cgagaaagtc ggagaagcca ctgaaactgc 1680
tcttatcgtt ctgtcgaga agatgaatgt tttcggAAC tcgaaAGCCG gacttcacc 1740
aaaggagctc ggaggagttt gcaaccgtgt catccaacaa aaatgaaaga aggagttcac 1800
actcgagtt tcccgatgc gtaaatccat gtccgcctac tgcttcccag cticggagg 1860
atctggagcc aagatgtcg tgaagggagc cccagaagga gttctcgaa gatgcaccca 1920
cgtcagagtt aacggacaaa aggttccact cacctctgcc atgactcaga agattgtga 1980
ccaatgcgtg caatacgaa ccggaaagaga tacccttcgt tgtcttcgc tcggccagca 2040
caatggatct cgagggatct tccatactca ccagttctgc gcctgcaggt cgccgcgc 2100
actctctaga cgcgtaaagct tactagcata accccttggg gcctctaaac ggtcttgag 2160
gggtttttt agcttctcg tctatagtg aatcatggtc atagctgtt cctgtgtaa attgttatcc 2280
tcacctaatt agcttggcg gtcacaatt ccacacaaca tacgagccgg aagataaaag tgtaaagcct ggggtgccta 2340
atagtgagc taactcacat taatttcgtt gtcgtattac agcttgagta ttctatagtg 2220
cctgtcggtc cagctgcatt aatgaatcg ccaacgcgcg gggagaggcg gtttgcgtat 2460
tggcgctct tccgttccct cgctcactga ctcgcgtgc tcggcgttc ggctcgccg 2520
agcgtatca gtcactcaa aggcgttaat acggttatcc acagaatcag gggataacgc 2580
aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 2640
gttgcgttt ttcgataggc tccggcccccc tgacgagcat cacaAAAATC gacgctcaag 2700
tcagaggtgg cgaaacccga caggactata aagataccag gcgttcccc ctgaaagctc 2760
cctcggtcgc tctctgttc cgaccctgcg gcttaccggc tacctgtccg ccttctccc 2820
ttcgggaagc gtggcgctt ctcatacgct acgtgttagg tatctcagtt cggtgttaggt 2880
cgttcgctcc aagctgggct gtgtgcacga acccccccgtt cagcccgacc gctgcgcctt 2940
atccggtaac ttcgttctt agtccaaccc ggtaaagacac gacttatcgc cactggcagc 3000
agccactgtt aacaggatta gcagagcgg gtagttaggc ggtgctacag agttttgaa 3060
gtggtggcct aactacggct acactagaag gacagtattt ggtatctgcg ctctgctgaa 3120
gccagttacc ttcggaaaaaa gagttggtag ctcttgatcc ggcaaaacaaa ccaccgctgg 3180
tagcgggtgg tttttgttt gcaaggcgc gattacgcgc agaaaaaaaaag gatctcaaga 3240
agatcctttg atctttcta cggggctcga cgctcagtgg aacgaaaact cacgttaagg 3300
gattttggtc atgagattat caaaaaggtt cttcacctag atccttttaa attaaaaatg 3360
aagttttaaa tcaatctaaa gtatataatg gtaaaacttgg tctgacagtt accaatgtt 3420
aatcagttag gCACCTATCT cagcgatctg tctatttcgt tcatccatag ttgcctgact 3480
ccccgtcgtagataacta cgatacggg gggcttacca tctggcccca gtgcgtcaat 3540
gataccgcga gaccacgcg caccggctcc agatttatac gcaataaaacc agccagccgg 3600
aaggcccgag cgccagaatgt gtcctgcacac tttatccgc tccatccagt ctattaattg 3660
ttgcccggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcacg ttgttggcat 3720
tgctacaggc atcggtgtt cacgcgtcgtc gtttggtag gcttcattca gctccggttc 3780
ccaacgcata aggcgtta catgatcccc catgttgc aaaaaagcgg ttagctcctt 3840
cggtcctccg atcggtgtca gaagtaagtt ggcgcagtg ttatcactca tggttatggc 3900
agcaactgcata aattctctt ctgtcatcc atccgtaaaga tgctttctg tgactgggtga 3960
gtactcaacc aagtcttctt gagaataccg cgccggcga ccgagttgtcttgcggc 4020
gtcaatacgg gataatagtg tatgacatag cagaacttta aaagtgcgtca tcatggaaa 4080
acgttcttcg gggcgaaaac tctcaaggat cttaccgtg ttgagatcca gttcgatgt 4140
acccactcgat gCACCCAACT gatcttcgcg atctttact ttaccaggcg tttctgggtg 4200
agcaaaaaca ggaaggcggaa atgcccggaaa aaagggata agggcgcacac gggaaatgtt 4260
aatactcata ctcttcctt ttcaatatta ttgaagcatt tattcagggtt attgtctcat 4320
gagcggatac atatttgaat gtatTTAGAA aaataaaacaa ataggggttc cgccgcacatt 4380
tccccggaaa gtggccacctg acgtctaaaga aaccattatt atcatgacat taacctataa 4440
aaataggcgt atcacgaggc ctttcgtct cgccgttcc ggtgatgacg gtgaaaacct 4500
ctgacacatg cagctcccg agacgtcgtac agcttgcgtg taagcggatg ccgggagcag 4560
acaagccgt cagggcgcgt cagcgggtgt tggcgggtgt cggggctggc ttaactatgc 4620
ggcatcagag cagattgtac tga 4643

<210>

<211> 4454

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX104

<400> 5

gagtgcacca tatgcgggtgaaataccgc acagatgcgt aaggagaaaa taccgcattca 60
ggcgaattttaa accaataggc cggaaatcgcc aaaatccctt ataaatccaa agaatacgacc 120
tcatttttaa accaataggc cggaaatcgcc aaaatccctt ataaatccaa agaatacgacc 180
gagatagggt tgtagtgttgc tccaggttgg aacaagagtc cactattaa gaacgtggac 240
tccaaacgtca aaggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
cccaaataaa gtttttgcg gtcgagggtgc cgtaaagctc taaatcgaa ccctaaagg 360
agcccccgat ttagagcttg acggggaaag cggcgaaacg tggcgagaaa ggaagggaag 420
aaagcgaaaag gaggcgccgc tagggcgctg gcaagtgtag cggtcacgct gcgcgttaacc 480
accacaccccg cccgcgtttaa tgccgcgtc cagggcgatg ccattcgcca ttcaaggctgc 540
gcaactgttgc ggaaggcgatc tcggtgccgg cctcttcgtt attacgccag ctggcgaaag 600
ggggatgtgc tgcaaggcgatc ttaagttggg taacgcccagg gttttccag tcacgacgtt 660
gtaaaacgc ggcgcgtgaa ttgttaatacg actcactata gggcgaaattc aaaaaacccc 720
tcaagaccccg tttagaggcc ccaagggtt atgctgttgc attctgcagg gtacccgggg 780
atcctctaga gatccctcgat cctcgagatc cattgtgttgc gaccgtggta ctcttatgg 840
gctcggaaatc tcgccaatcg tcacttctgg atttatcatg caacttctcg cccgagccaa 900
gatcatcgaa gtcggagaca caccaaaagg ccgtgtctt ttcaacggag cccagaaatg 960
taagccgaaa agtgtgttgc ttcaatctctt aatttttgcgatc cttttcgttgc ttccgtatgg 1020
tcatcaactgttgc gagaacgatc attgtctacg tcatgtccgg actctacggag gagccatcg 1080
aaatcgggagc tggaaatctgt ctccttatcg tcgttccaaact cggttatttgc ggtctcatecg 1140
tcctccttctt cgacgagctt ctccaaaagg gatatggctt cggatccggaa atttctctt 1200
tcatttgcac caacatctgt gaaaccatttgc tctggaaaggc attctcccg gcaacaatga 1260
acaccggacg tggaaacggatc ttcaaggcgatc ccgttcatcg tcttttccat ctcttgcc 1320
cccgctccga caaggtccgt gcccctcgat aggctttcta ccgtcaaaac ctccaaact 1380
tgatgaactt gatggctact ttccctcgat ttgcgggtt tatctacttc caaggattcc 1440
gtgtcgaccc cccaaatcaag tctggccgtt accgtggaca atacagcgc tacccaaatca 1500
agctttcttca caccctcaac attccaaatca tccttcaatcg tgcgtctcgat tccaaacctt 1560
acgttatctc tcagggttgc tgcatctcgat tagtaccgtt agatgtttat ctttctctag 1620
aggggtcaagt tggccgagaa attttttgcgatc ttcaatttgcgatc agtctgtatgg aaaaatgttta 1680
tttttcagat gtcggccggatc aagtttgcgatc gaaacttctt catcaacctt ctccgttacct 1740
ggtccgataa caccggatatac agaagctacc caactggagg actctgttac tatcttttgc 1800
caccagatc tcttggacac atcttgcgatc accaaatcca ctgcaccacg acaatggatc 1860
tcgagggtatc ttccatcacctt accaggctcgat cggccgtcagg tcgcggccgc gactctctag 1920
acgcgttaagc ttacttagcat aacccttgcgatc gggctctaa cgggtcttgc ggggtttttt 1980
gagctttctcg ccctatagtg agtctgttgc cagtttgcgtt attctatagt gtcacctaaat 2040
tagcttggcg taatcatgtt catagctgtt tcctgtgtgc aatttttgcgatc cgttcacaat 2100
tccacacaac atacgagccg gaagcataaa gtgtaaagcc tgggggtgcct aatgagtgc 2160
ctaactcaca ttaatttgcgt tgcgtctact gcccgtttt cagtcggaa acctgtcg 2220
ccagctgcgtat taatgaatcg gccaacgcgc ggggagagggc ggtttgcgtt ttggggcgctc 2280
ttccgttcc tgcgtctactg actcgctgcg ctgggtcgat cggctgcggc gagcgggttac 2340
agctcactca aaggcggtaa tacgggttac cacaatca ggggataacg caggaaagaa 2400
catgtgagca aaggccgcg aaaaaggcccg gaaccgttac aaggccgcgt tgctggcgat 2460
tttcgatagg ctccggccccc ctgacgagca tcacaaaaat cgacgtctaa gtcagaggtt 2520
gcgaaaccccg acaggacttca aagatccaccc ggcgttcccg cctggaaatcg cctctcgatc 2580
ctctctgtt ccgaccctcgat cgcgttaccgg atacctgttgc gccttctcc ctccggaaag 2640
cgtggcgatc ttctcatagtc cagctgttagt gtatctcgat tgggttgcgtt tgcttgcgtc 2700
caagctgggc tgggtgcacg aaccctccgttca gggccgttgc cgttgcgtt tttccggat 2760
ctatcgatcc ttttttgcgtt ggttttgcgtt ggttttgcgtt ggttttgcgtt ggttttgcgtt 2820
taacaggatt agcagagcgatc ggtatgttgc cgggttgcgtt ggttttgcgtt ggttttgcgtt 2880
taactacggc tacacttagaa ggacgttgcgtt ggttttgcgtt ggttttgcgtt ggttttgcgtt 2940
cttccggaaaa aggttggatc gtcgttgcgtt cggccaaacaa accaccgtcgatc gtcgttgcgtt 3000
ttttttgtt tgcaaggcgatc agattacgcgatc cggccaaacaa accaccgtcgatc gtcgttgcgtt 3060
gatctttctt acgggggtctg acgctcgttgc ggttttgcgtt ggttttgcgtt ggttttgcgtt 3120

cat gagat taaaaggat cttcacca gatcccttta aattaaaaat gaagttttaa 3180
 atcaatctaa agtatatacg agttaacttg gtctgacagt taccaatgtc taatcagtga 3240
 ggcacctatc tcagcgatct gtctatttcg ttcatccata gttgcctgac tccccgtcgt 3300
 gtagataact acgatacggg agggettacc atctggccc agtgcgtcaa tgataccgcg 3360
 agaccacgc tcaccggctc cagatttac agaataaaac cagccagccg gaagggccga 3420
 gcgcagaagt ggtcctgca ctttatccgc ctccatccag tctattaatt gttgccggga 3480
 agctagagta agtagttcgc cagttaatag ttgcgcacac gttgttggca ttgtctacagg 3540
 catcggtg tcacgctcg cgttggtat ggcttcattc agtccgggtt cccaaacgatc 3600
 aaggcgagtt acatgatccc ccatgttgc caaaaaagcg gttagctcct teggctctcc 3660
 gatcggtgtc agaagtaagt tggccgcagt gttatcactc atggttatgg cagcaactgca 3720
 taattctctt actgtcatgc catccgtaag atgctttct gtgactgggt agtactcaac 3780
 caagtcatc tgagaatacc ggcgcggcg accgagttgc tcttgcggg cgtaataacg 3840
 ggataatagt gtatgacata gcagaacttt aaaagtgcgc atcattggaa aacgttcttc 3900
 ggggcgaaaaa ctctcaagga tcttaccgcgt gttgagatcc agtgcgtatg aaccactcg 3960
 tgcacccaac tgatcttcg catctttac ttccaccaggc gtttctgggt gagaaaaaac 4020
 aggaaggcaa aatgcgcaca aaaaggaaat aaggggcgaca cggaaatgtt gaataactcat 4080
 actcttcattt ttcaatattt attgaagcat ttatcagggtt tattgtctca tgagcggata 4140
 catatttgcgaa tgatatttgcgaaa aataaaaca aatagggtt ccgcgcacat ttccccggaaa 4200
 agtgcacact gacgtctaag aaaccattat tatcatgaca ttaacctata aaaataggcg 4260
 tatcacgagg cccttcgctc tcgcgcgtt cgggtatgac ggtgaaaacc tctgacacat 4320
 gcagctcccg gagacggctca cagcttgtct gtaagcggat gccggagca gacaagcccg 4380
 tcagggcgcg tcagcggtt ttggcggtt tcggggctgg cttaactatg cggcatcaga 4440
 gcagattgtatc 4454

<210> 6

<211> 4701

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGZ18

<400> 6

accccagctt cttgtacaaa gtgggtatct ttccagcaca atggatctcg agggatcttc 60
 cataccctacc agttctgcgc ctgcaggatcg cggccgcgcac tctctagacg cgtaagctta 120
 ctagcataac cccttggggc ctctaaacgg gtcttgaggg gtttttttagg ctctcgccc 180
 tatagtgagt cgtattacag cttgagtatt ctatagtgtc acctaaatag cttggcgtaa 240
 tcatgtcat agctgttcc tgggtgaaat ttttatccgc tcacaattcc acacaacata 300
 cgagccggaa gcataaaatgtg taaaggctgg ggtgcctaatt gaggatgtca actcacattaa 360
 attgcgttgc gctactgccc cgtttccag tcgggaaacc tgcgtgtccca gctgcattaa 420
 tgaatcgcc aacgcgcggg gagaggcggt ttgcgtattt ggcgccttc cgcttcctcg 480
 ctcactgact cgctgcgc cgtcgttccg ctgcggcgag cggtatcagc tcactcaaag 540
 gcggtataac ggttatccac agaatcaggg gataacgcag gaaagaacat gtgagcaaaa 600
 ggccagcaaa aggccaggaa cgtaaaaaag gcccgcgttgc tggcggtttt cgataggctc 660
 cgccccccctg acgagcatca caaaaatcgca cgcctcaagtc agagggtggcg aaacccgaca 720
 ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgtc tcctgttccg 780
 accctgcgc ttacccgata cctgtccgc ttctccctt cgggaagcgt ggcgtttct 840
 catagctcac gctgttagtca tctcagttcg gttgttagtgc ttgcgtccaa gctgggtgt 900
 gtgcacgaac ccccccgtca gcccgcaccgc tgcgccttat cggtaacta tcgtctttag 960
 tccaaaccggg taagacacga cttatcgcca ctggcagcag ccactgttac caggattagc 1020
 agagcgaggt atgttaggcgg tgcgtacagag ttcttgaagt ggtggcttaa ctacggctac 1080
 actagaagga cagtatttgc tatctgcgtc ctgcgtgaagc cagttacattt cgaaaaaaaga 1140
 gttggtagct ctgtatccgg caaacaacc accgctggta ggggtgggtt ttttgggtgc 1200
 aagcagcaga ttacgcgcag aaaaaaaggat tctcaagaag atcctttagt cttttctacg 1260
 gggtctgacg ctcagtggaa cggaaactca cgttaaggaa ttttggtcat gagattatca 1320
 aaaaggatct tcaccttagat ctttttaat taaaatgaa gttttaaatc aatctaaatgt 1380
 atatatgtatc aaacttggtc tgacagttac caatgcttaa tcagtggaggc acctatctca 1440
 gcgatctgtc tatttcgttc atccatagtt gcctgactcc cggcgtgtatc gataactacg 1500

atacgggagg gcttaccatc tggccccagt gctgcataatga taccgcgaga cccacgctca 1560
 ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtgg 1620
 cctgcactt tatccgcctc catccagtct attaattgtt gcccggaaagc tagagtaat 1680
 agttcgccag ttatagttt ggcacaacgtt gtggcattt ctacagcat cgtgggtgtca 1740
 cgctcgctgt ttggatggc ttcatcgc tccgggtccc aacgatcaag gcgagttaca 1800
 tgatccccca tggtgcaaaa aaaaagcggtt agtccttcg gtcctccat cgttgtcaga 1860
 agtaagttgg cccgactgtt atcaactatg gtatggcag cactgcataa ttcttctact 1920
 gtcatgccat ccgtaaagatg cttttctgtt actgggtgatg actcaaccaa gtcattctga 1980
 gaataccgcg cccggcgacc gagttgtct tggccgggtt caataccggaa taatagtgt 2040
 tgacatagca gaactttaaa agtgctcattc atggaaaaac gttttccggg gcgaaaactc 2100
 tcaaggatct taccgctgtt gagatccagt tcgatgttaac ccactcgatc acccaactga 2160
 tcttcagcat cttttacttt caccagcggtt tctgggtgag caaaaacagg aaggcaaaaat 2220
 gccgcaaaaaa agggataaaag ggcgacacgg aaatgttgg tactcatact ctttcctttt 2280
 caatattattt gaagcattttt tcagggttat tggctcatga gggatcat atttgaatgt 2340
 atttagaaaaa ataaacaaat aggggttccg cgacatattt cccgaaaagt gccacactgac 2400
 gtctaagaaa ccattattat catgacatta acctataaaa ataggcgat cacgaggccc 2460
 tttcgctctcg cgctttcg tggatgacgtt gaaaacctct gacacatgca gctccggag 2520
 acggtcacag ctgtctgtt agcggatgcc ggagcagac aagccgtca gggcgctca 2580
 gccccgggtt gccccgggtt gggctggctt aactatgcgg catcagagca gattgtactg 2640
 agagtcacc atatgcgggtt tggaaataccg cacagatgcg taaggagaaa ataccgcata 2700
 aggcgaaatt gtaaaacgttta atattttgtt aaaattcgcg taaaatattt gttaaatcag 2760
 ctcatttttt aaccaatagg ccgaaatccgg caaaatccct taaaatcaa aagaatagac 2820
 cgagataggg ttgagtgtt gttccagttt gacaagagat ccactattaa agaacgtgga 2880
 ctccaaacgtc aaaggcgaa aaaccgtcta tcaggcgat gggccactac gtgaaccatc 2940
 accccaaatca agtttttgc ggtcgagggtt ccgtaaagct ctaaaatcgga accctaaagg 3000
 gagcccccgat tttagagctt gacggggaaa gcccgcgaac gtggcgagaa aggaaggaa 3060
 gaaagcgaaa ggagcggggcg cttagggcgat ggcaagtgtt ggggtcacgc tgccgttaac 3120
 caccacaccc gcccgcgttta atgcggcgat acaggcgcg tccattcgat attcaggctg 3180
 cgcaactgtt gggaaaggcg atcggtgcgg gccttcgcg tattacgca gctggcgaaa 3240
 gggggatgtt ctgcaggcg attaagttgg ttaacgcccgg ggtttccca gtcacgacgt 3300
 tggtaaaacgtt gggccagtgtt attgtataac gactcaatg aggccgaaatt caaaaaaaaacc 3360
 ctcaagaccc gtttagagggc cccaaagggtt tatgcttagt aattctgcag ggtacccggg 3420
 gatcctctag agatccctcg acctcgagat ccattgtgtt gggaaaggctt tgccaggctg 3480
 gcaaggccacg ttgggtgggtt ggcaccatcc tccaaaatca acaagttgtt aaaaaaaaaacg 3540
 aggctatgcc aagtacatgtt cgattgcgtt cgcgttcgtt atgttggctg tggtagtcgc 3600
 taccagcagt caaattgtt tcgagatgtc gtttttacat tattccctca tcctgattac 3660
 gacaattttc agctgttctc gctccatcat ctctcttcat tgcacaatg gtcggaatct 3720
 tcttccttgc tgcatgtctt catccaaaag aattcagcaatg tattatccat ggtgtcgat 3780
 tcttccttcat gattccatctt acatatgtgt tccctactt atattcgatc atcaatctca 3840
 acgttatcac gtggggactt cgtgaagctg tcgctaaaggc aacgggacaa aagacgaaaa 3900
 aaggccctat ggaacaattt atagacagag tgattgatat tggaaaaag ggattcagat 3960
 taatcagttt tggggagaag aaggaacatg aagagagacg agagaaaaatg gaaaagaaaa 4020
 tgcagagaat ggagctagcc ttgagaagta ttgaggtt ttttaactttt agaaaatgtt 4080
 attaataat ttatTTTCAAGTGGTCCGACGTGAAGAA AATTCTCGAT GCAACAGAGG 4140
 agaaggagaa acgtgaagaa gaaaactcaaa ctgcagattt tccgatttgc gagaacgttag 4200
 agaagactca aaaaagagatt cagaaggca accgttatgtt gtggatgaca agtcatagct 4260
 tggaaatgg tgaacgggaa aaactgaaaaa gtgcggaaaaa ggtttctgg aacgagctca 4320
 tcaatgcata tctggaaaccg atcaagacga cggcagctga aatgaaaagcc gtcgcccgaag 4380
 gattggcttctc tctacggaaat cagaatgtt tcaactattct tctcgatcat tctcttctt 4440
 ctcttcgttcat ctttttgcattt cagaacacaca aaaaatgtgtt cagcatcaag ttctcgccaa 4500
 tcagtaagca atattacattt tttttttttt tttttttttt ttcttagaaaa 4560
 cttccgatgg acggaaaatgtt atgagatgac tggacaatc gaggaaaccg atgaaccatt 4620
 aaaaatagat ccacttggaa tggaaattgtt tggatggatgtt cttttttttt tttttttttt 4680
 aactctcgatc atgcttctcc a 4701

<210> 7

<211> 25

<212> DNA

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide primer C04H5.6F

<400> 7

tgctcagaga gtttctcaac gaacc

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer C04H5.6R

<400> 8

caatgttagt tgctaggacc acctg

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bF

<400> 9

cagccgatct ccgtcttgtg

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bR

<400> 10

ccgaggggcaa gacaacgaag

20

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15F

<400> 11

accgtggtagt tcttatggag ctcg

24

<210> 12

11

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15R

<400> 12
tgcagtggat tgggtcttcg

20

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2F

<400> 13
ggggacaaagt ttgtacaaaa aaggcaggcta tgccaaagtac atgtcgattt cg

52

<210> 14
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2R

<400> 14
ggggaccact ttgtacaaga aagctgggtt ggagaagcat tccgagagtt tg

52

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/13149

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7 C12N15/10 C12N9/22 C07K14/435 C12N15/66 C12N15/70 C12N1/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 7 C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
BIOSIS, EPO-Internal, WPI Data, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TIMMONS L ET AL: "Specific interference by ingested dsRNA" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 395, no. 6705, 29 October 1998 (1998-10-29), page 854 XP002103601 ISSN: 0028-0836 the whole document	1-4, 12-21, 23-25, 28-31, 34-39
A	FIRE A ET AL: "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> " NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 391, 19 February 1998 (1998-02-19), pages 806-811, XP002095876 ISSN: 0028-0836 cited in the application the whole document	1-4
	---	-
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents :</p> <p>'A' document defining the general state of the art which is not considered to be of particular relevance</p> <p>'E' earlier document but published on or after the International filing date</p> <p>'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>'O' document referring to an oral disclosure, use, exhibition or other means</p> <p>'P' document published prior to the international filing date but later than the priority date claimed</p>		
<p>"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the International search		Date of mailing of the international search report
5 July 2001		20/07/2001
Name and mailing address of the ISA		Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/13149

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHARP PHILLIP A: "RNAi and double-strand RNA." GENES & DEVELOPMENT, vol. 13, no. 2, 15 January 1999 (1999-01-15), pages 139-141, XP002171268 ISSN: 0890-9369 the whole document	1-4
A	RAY C ET AL: "GUT-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF A CAENORHABDITIS ELEGANS CYSTEINE PROTEASE GENE" MOLECULAR AND BIOCHEMICAL PARASITOLOGY, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 51, 1992, pages 239-249, XP000572340 ISSN: 0166-6851 abstract	2-4, 8
A	RAND J B ET AL: "GENETIC PHARMACOLOGY: INTERACTIONS BETWEEN DRUGS AND GENE PRODUCTS IN CAENORHABDITIS ELEGANS" METHODS IN CELL BIOLOGY, LONDON, GB, vol. 84, 1995, pages 187-204, XP000956211 page 190, paragraph 1 -page 194, paragraph 4	1-4, 8
A	AVERY LEON ET AL: "The Caenorhabditis elegans unc-31 gene affects multiple nervous system-controlled functions." GENETICS, vol. 134, no. 2, 1993, pages 455-464, XP001011453 ISSN: 0016-6731 the whole document	2-4, 8
A	TAGESSON C ET AL: "INFLUENCE OF SURFACE-ACTIVE FOOD ADDITIVES ON THE INTEGRITY AND PERMEABILITY OF RAT INTESTINAL MUCOSA" FOOD AND CHEMICAL TOXICOLOGY, vol. 22, no. 11, 1984, pages 861-864, XP001009621 ISSN: 0278-6915 the whole document	8
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/13149

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	LYON CHRISTOPHER J ET AL: "The <i>C. elegans</i> apoptotic nuclease NUC-1 is related in sequence and activity to mammalian DNase II." GENE (AMSTERDAM), vol. 252, no. 1-2, 11 July 2000 (2000-07-11), pages 147-154, XP001009494 ISSN: 0378-1119 abstract; figure 3 page 151, right-hand column, paragraph 2 -page 153, right-hand column, paragraph 2 ---	6,7
P,X	WO 00 01846 A (MORTIER KATHERINE ;DEGEN NV (BE); BOGAERT THIERRY (BE); PLAETINCK) 13 January 2000 (2000-01-13) cited in the application page 8, line 9 -page 10, line 22 page 12, line 14 -page 23, line 2 figures 5,9; examples 1-4 ---	1-4, 12-21, 23-25, 28-31, 34-39
P,X	WO 00 63425 A (FEICHTINGER RICHARD ;BEGHYN MYRIAM (BE); DEGEN NV (BE); BOGAERT T) 26 October 2000 (2000-10-26) abstract page 2, line 14-30 page 6, line 18-33 page 7, line 12 -page 9, line 28 page 12, line 20 -page 13, line 25; example 3 ---	2-5,8,9, 29-33
T	TIMMONS LISA ET AL: "Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in <i>Caenorhabditis elegans</i> ." GENE (AMSTERDAM), vol. 263, no. 1-2, 2001, pages 103-112, XP001009512 ISSN: 0378-1119 the whole document ---	1-4, 12-21, 23-26, 28-31, 34-39

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/13149

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0001846	A 13-01-2000	AU 4907999 A		24-01-2000
		EP 1093526 A		25-04-2001
		GB 2349885 A		15-11-2000
		NO 20010019 A		05-03-2001
WO 0063425	A 26-10-2000	AU 3984600 A		02-11-2000
		GB 2351152 A		20-12-2000